IL17A and systemic sclerosis: Together, these findings delineate a cross-scale pathogenic axis in which PPAR-γ–mediated regulation of both adaptive and innate IL-17 production links genetic susceptibility, cellular dysregulation, and clinical phenotypes in SSc and PsO.